-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
KIN101
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/610753-87-2.gif)
| Category | Hepatitis C Virus (HCV) |
| CAS | 610753-87-2 |
| Description | KIN101 is a potent RNA viral inhibitor with IC50s of 2 μM, >5 μM for influenza virus and Dengue virus (DNV), respectively. |
Product Information
| Synonyms | 610753-87-2|3-(4-Bromophenyl)-7-[(methylsulfonyl)oxy]-4-oxo-4H-chromene|KIN101|MFCD03993951|[3-(4-bromophenyl)-4-oxochromen-7-yl] methanesulfonate|SCHEMBL470779|3-(4-bromophenyl)-4-oxochromen-7-yl methylsulfonate|KIN 101|ZINC2400798|AC6463|STK922769|AKOS002164529|NCGC00320760-01|SY032153|HY-126113|CS-0090568|AB01315693-02|SR-01000260856|SR-01000260856-1|[3-(4-bromophenyl)-4-oxo-chromen-7-yl] methanesulfonate|3-(4-bromophenyl)-4-oxo-4H-chromen-7-yl methanesulfonate |
| Molecular Weight | 395.22 |
| Molecular Formula | C16H11BrO5S |
| Canonical SMILES | CS(=O)(=O)OC1=CC2=C(C=C1)C(=O)C(=CO2)C3=CC=C(C=C3)Br |
| Purity | 99.36% |
| Solubility | In Vivo: 1.Add each solvent one by one:10% DMSO >> 90%corn oil Solubility: ≥ 2.08 mg/mL (5.26 mM); Clear solution |
| Appearance | White to off-white (Solid) |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Complexity | 586 |
| Exact Mass | 393.95106 |
| In Vitro | KIN 101 (10 μM; 24 hours) causes a significant decrease in the NP protein abundance. KIN 101 (10 μM; 18 hours) shows a >1 log decrease in HCV RNA levels. KIN 101 (0.01, 0.1, 1, 10, 100 μM) has a significant and dose-dependent effect on the formation of foci and has an IC50 of 0.2 μM. KIN 101 (5, 10, 20, 50 μM; 4 hours) causes a dose-dependent decrease in influenza virus infection in MRC5 cells. KIN 101 results in a significant increase in the levels of ISGs as well as other proteins downstream of IRF activation such as RIG-I and MDA5. KIN101 (0.1-100 μM; 18 hours) shows the antiviral activity against hepatitis C virus (HCV). |
| Target | IC50: 2 μM (influenza virus) and >5 μM (DNV) |
| XLogP3-AA | 3.4 |
